MABWELL-B Shares Surge on Strategic Collaboration in Ophthalmology

Stock News06-17

Shares of MABWELL-B (ASX: 02493) have risen by more than 3%. At the time of writing, the stock is up 2.72% to HK$26.48, with a turnover of HK$6.48 million.

The increase follows news of a strategic partnership. The company announced that its majority-owned subsidiary, MABWELL Vision, has entered into a strategic collaboration with VivaVision Biotech, a leading domestic developer of small-molecule ophthalmic drugs.

The collaboration will be comprehensive and in-depth, focusing on addressing unmet clinical needs in two core areas: ocular inflammation and ocular immunology.

MABWELL-B's portfolio includes several retinal products, such as the novel anti-VEGF monoclonal antibody 9MW0211, a biosimilar of adalimumab, and a biosimilar of aflibercept. Its pipeline also covers mature drugs for ocular immunology, retinal diseases, dry eye, and ocular surface conditions.

VivaVision Biotech is a clinical-stage innovative drug company specializing in ophthalmology. It has established a unique R&D platform for ophthalmic innovation, with several self-developed novel drug candidates already in clinical stages.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197090310?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 11:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197090310","market":"nz","top_or_hot":-1,"title":"MABWELL-B Shares Surge on Strategic Collaboration in Ophthalmology","media":"Stock News","content":"<p>Shares of <b>MABWELL-B</b> (<b>ASX: 02493</b>) have risen by more than 3%. At the time of writing, the stock is up 2.72% to HK$26.48, with a turnover of HK$6.48 million.<br><br>The increase follows news of a strategic partnership. The company announced that its majority-owned subsidiary, MABWELL Vision, has entered into a strategic collaboration with VivaVision Biotech, a leading domestic developer of small-molecule ophthalmic drugs.<br><br>The collaboration will be comprehensive and in-depth, focusing on addressing unmet clinical needs in two core areas: ocular inflammation and ocular immunology.<br><br>MABWELL-B's portfolio includes several retinal products, such as the novel anti-VEGF monoclonal antibody 9MW0211, a biosimilar of adalimumab, and a biosimilar of aflibercept. Its pipeline also covers mature drugs for ocular immunology, retinal diseases, dry eye, and ocular surface conditions.<br><br>VivaVision Biotech is a clinical-stage innovative drug company specializing in ophthalmology. It has established a unique R&D platform for ophthalmic innovation, with several self-developed novel drug candidates already in clinical stages.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MABWELL-B Shares Surge on Strategic Collaboration in Ophthalmology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMABWELL-B Shares Surge on Strategic Collaboration in Ophthalmology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-17 11:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>MABWELL-B</b> (<b>ASX: 02493</b>) have risen by more than 3%. At the time of writing, the stock is up 2.72% to HK$26.48, with a turnover of HK$6.48 million.<br><br>The increase follows news of a strategic partnership. The company announced that its majority-owned subsidiary, MABWELL Vision, has entered into a strategic collaboration with VivaVision Biotech, a leading domestic developer of small-molecule ophthalmic drugs.<br><br>The collaboration will be comprehensive and in-depth, focusing on addressing unmet clinical needs in two core areas: ocular inflammation and ocular immunology.<br><br>MABWELL-B's portfolio includes several retinal products, such as the novel anti-VEGF monoclonal antibody 9MW0211, a biosimilar of adalimumab, and a biosimilar of aflibercept. Its pipeline also covers mature drugs for ocular immunology, retinal diseases, dry eye, and ocular surface conditions.<br><br>VivaVision Biotech is a clinical-stage innovative drug company specializing in ophthalmology. It has established a unique R&D platform for ophthalmic innovation, with several self-developed novel drug candidates already in clinical stages.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1197090310","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197090310","pubTimestamp":1781667890,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of MABWELL-B (ASX: 02493) have risen by more than 3%. At the time of writing, the stock is up 2.72% to HK$26.48, with a turnover of HK$6.48 million.The increase follows news of a strategic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","02493":"迈威生物-B"},"translate_title":"MABWELL-B股价因眼科战略合作而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02493":1},"content_text":"Shares of MABWELL-B (ASX: 02493) have risen by more than 3%. At the time of writing, the stock is up 2.72% to HK$26.48, with a turnover of HK$6.48 million.The increase follows news of a strategic partnership. The company announced that its majority-owned subsidiary, MABWELL Vision, has entered into a strategic collaboration with VivaVision Biotech, a leading domestic developer of small-molecule ophthalmic drugs.The collaboration will be comprehensive and in-depth, focusing on addressing unmet clinical needs in two core areas: ocular inflammation and ocular immunology.MABWELL-B's portfolio includes several retinal products, such as the novel anti-VEGF monoclonal antibody 9MW0211, a biosimilar of adalimumab, and a biosimilar of aflibercept. Its pipeline also covers mature drugs for ocular immunology, retinal diseases, dry eye, and ocular surface conditions.VivaVision Biotech is a clinical-stage innovative drug company specializing in ophthalmology. It has established a unique R&D platform for ophthalmic innovation, with several self-developed novel drug candidates already in clinical stages.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197090310","isCrawlerRequest":true}